Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Novanta's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Novanta's regulatory disclosures and financial reporting.
Novanta Inc.’s Chief Financial Officer Robert Buckley reported multiple equity transactions on common stock and equity awards. He received a grant of 11,990 Restricted Stock Units, each convertible into one common share upon vesting in three equal installments on February 20 of 2027, 2028, and 2029.
He also exercised derivative awards into common stock, including Restricted Stock Units and stock options that had previously vested, and had 93,814 common shares held directly afterward. To cover taxes, 1,185 shares were disposed of at about $145.96 per share, and additional open-market sales totaling 1,423 shares occurred around $140–$144 per share under a pre-established Rule 10b5-1 trading plan. Buckley also reported 36,219 common shares held indirectly through the Buckley Family Irrevocable Trust.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported multiple equity transactions involving company stock on February 20, 2026. He received a grant of 26,035 Restricted Stock Units (RSUs), each representing one Novanta common share upon vesting. On the same date, he exercised 5,322 RSUs, converting them into 5,322 shares of common stock, and disposed of 2,574 common shares to satisfy tax obligations at a price of $145.96 per share. After these transactions, he directly owned 64,156 common shares and 10,645 RSUs, and indirectly held 54,382 common shares through the Matthijs Glastra 2021 Irrevocable Trust. The new RSU grant vests in three equal installments on February 20, 2027, February 20, 2028, and February 20, 2029.
Novanta Inc. Co-Chief Operating Officer Charles Guy Ravetto Jr. reported equity award and related share transactions on February 20, 2026. He acquired 1,633 common shares through the exercise of Restricted Stock Units and received a new grant of 7,537 Restricted Stock Units.
After the RSU conversion, his direct common stock holdings were 15,266 shares, before a 480-share tax-withholding disposition at $145.96 per share reduced that balance to 14,786 shares. Following the transactions, he also directly holds 3,269 previously awarded Restricted Stock Units and a new award of 7,537 Restricted Stock Units, each representing one common share upon vesting over scheduled dates from 2026 through 2029.
Novanta Inc. Co-Chief Operating Officer John Lesica reported multiple equity transactions on February 20, 2026. He received a grant of 7,537 Restricted Stock Units (RSUs), each representing one common share upon vesting. The RSUs vest in three equal installments on February 20, 2027, 2028, and 2029. He also exercised 1,633 RSUs into common stock and then had 480 common shares withheld at 145.96 per share to cover tax obligations, leaving him with 2,096 common shares held directly after these transactions.
Manganiello Alexander reported acquisition or exercise transactions in this Form 4 filing.
Novanta Inc. reported that its General Counsel, Alexander Manganiello, received a grant of 4,111 Restricted Stock Units on February 20, 2026. Each unit represents the right to receive one Novanta common share when it vests. The award vests in three equal installments on February 20, 2027, 2028, and 2029, providing long-term equity-based compensation that ties the executive’s interests to future company performance.
NOVANTA INC Chief Executive Officer Matthijs Glastra reported equity award activity involving performance stock units and common shares. On February 19, 2026, 7,825 Performance Stock Units were exercised, each converting into one common share, following Compensation Committee ratification based on 58.4% achievement of the performance target.
In connection with this vesting, 3,784 common shares were disposed of at $144.93 per share to satisfy tax obligations, a non‑open‑market, tax-withholding disposition. After these transactions, Glastra directly held 65,192 common shares, and an additional 54,382 common shares were held indirectly through the Matthijs Glastra 2021 Irrevocable Trust.
Novanta Inc Co-Chief Operating Officer Charles Guy Ravetto Jr reported equity award activity involving Performance Stock Units and common shares. On February 19, 2026, he exercised 722 Performance Stock Units at $0.00 per unit, converting them into 722 common shares.
The filing also shows a tax-withholding disposition of 251 common shares at a price of $144.93 per share, leaving him with 13,633 common shares held directly after these transactions. Footnotes state each Performance Stock Unit converts into one share and that the award size was set based on 58.4% achievement of a performance target.
NOVANTA INC Chief Financial Officer Robert Buckley exercised 2,935 Performance Stock Units into common shares, then used 1,420 shares to cover tax withholding at $144.93 per share. He now holds 92,549 shares directly and 36,219 shares indirectly through the Buckley Family Irrevocable Trust.
Novanta Inc. reports on its 2025 performance as a global supplier of precision technologies for medical and advanced industrial OEMs. For the year ended December 31, 2025, Automation Enabling Technologies generated revenue of $500.8 million with a gross profit margin of 47.8% and operating profit of $114.5 million, while Medical Solutions delivered revenue of $479.8 million with a 41.6% gross profit margin and operating profit of $51.2 million.
Medical end markets represented about 53% of revenue and advanced industrial about 47%. Backlog was approximately $481.2 million as of December 31, 2025. The company strengthened its balance sheet by issuing 12,650,000 6.50% tangible equity units at $50.00 per unit, recording net proceeds of $613.1 million, and by entering a new $1.0 billion credit facility maturing in June 2030. Novanta also acquired Keonn Technologies for a total purchase price of $75.1 million, expanding its RFID capabilities within the Medical Solutions segment. As of February 16, 2026, Novanta had 35,683,769 common shares outstanding and non‑affiliate market value of $3.50 billion based on June 27, 2025 pricing.
Novanta Inc. reported steady growth for the fourth quarter and full year 2025 while laying out an ambitious 2026 outlook. Fourth quarter 2025 revenue reached $258.3 million, up 8.5% year over year, with GAAP diluted EPS of $0.45 versus $0.46 and Adjusted diluted EPS rising 20% to $0.91. Adjusted EBITDA grew 17% to $60.7 million, supported by a 25% increase in customer bookings and a book-to-bill of 1.11x.
For full year 2025, revenue was $980.6 million, up 3.3%. GAAP diluted EPS declined to $1.47 from $1.77, but Adjusted diluted EPS improved 6.8% to $3.29 and Adjusted EBITDA increased to $221.0 million. Operating cash flow fell to $64.1 million from $158.5 million, mainly due to higher working capital from regionalizing manufacturing.
Novanta ended 2025 with $380.9 million of cash and $250.8 million of total debt, resulting in Net Debt of $(121.3) million. For 2026, the company guides GAAP revenue to $1,030–$1,050 million, Adjusted EBITDA to $245–$250 million and Adjusted diluted EPS to $3.50–$3.65, with operating cash flow of $145–$185 million, and expects mid‑single‑digit organic growth.